Skip to main content
main-content

Lung cancer

Lung cancer

03-09-2019 | Oncology | News | Article

Very high PD-L1 expression increases pembrolizumab benefit in NSCLC

Response is significantly and positively associated with PD-L1 expression in patients with non-small-cell lung cancer receiving first-line pembrolizumab, suggest the results of a retrospective analysis.

02-09-2019 | Oncology | Highlight | Article

Elevated cardiovascular risk seen in survivors of most common cancers

Survivors of the 20 most common site-specific cancers, including lung and prostate, are at increased risk for cardiovascular disease in the years that follow diagnosis and treatment, show data published in The Lancet.

30-08-2019 | Oncology | News | Article

No survival benefit with erlotinib–bevacizumab in stage IV NSCLC

Adding bevacizumab to erlotinib does not improve the outcomes of previously untreated patients with EGFR mutation-positive advanced non-small-cell lung cancer, finds a phase II trial.

28-08-2019 | Oncology | News | Article

Combining local and systemic therapy improves survival for advanced NSCLC

In patients with stage IV non-small-cell lung cancer, the addition of surgical resection or external beam radiotherapy/thermal ablation to systemic therapy increases overall survival versus systemic therapy alone, suggests a comparative effectiveness study.

27-08-2019 | Oncology | News | Article

Early promise for HIV drug–CRT combination in locally advanced NSCLC

The HIV protease inhibitor nelfinavir plus concurrent chemoradiotherapy has shown acceptable toxicity and promising efficacy in unresectable, stage IIIA/B non-small-cell lung cancer in a phase I/II trial.

23-08-2019 | Oncology | News | Article

Entrectinib gains two indications in USA

Details of this FDA decision are a click away

20-08-2019 | Oncology | News | Article

Study supports use of fosnetupitant in combination with palonosetron for CINV

A phase II trial shows that the intravenous prodrug fosnetupitant in combination with palonosetron reduces chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

19-08-2019 | Oncology | News | Article

Early data show promise for the FGFR inhibitor rogaratinib

The FGFR inhibitor rogaratinib is well tolerated and clinically active in patients with various tumor types selected for treatment on the basis of FGFR mRNA overexpression, phase I study data show.

16-08-2019 | Oncology | Main feed | News

EMA adopts new indications for pembrolizumab, atezolizumab

Click through to find out which additional patient groups can now receive these drugs

14-08-2019 | Oncology | News | Article

Nivolumab shows long-term clinical efficacy in Japanese patients with advanced NSCLC

Pooled long-term results from two multicenter phase II studies indicate that nivolumab is efficacious in Japanese patients with previously treated, stage IIIB/IV squamous or nonsquamous non-small-cell lung cancer.

12-08-2019 | Oncology | News | Article

Individuals with autoimmune disease ‘good candidates’ for cancer immunotherapy

A French database analysis lends further support for the use immune checkpoint inhibitors for cancer in patients with pre-existing autoimmune disease.

07-08-2019 | Oncology | News | Article

Larotrectinib first tumor-agnostic treatment to get EMA nod

Click through for the details of this decision

02-08-2019 | Oncology | News | Article

LIPI score associated with survival in metastatic NSCLC irrespective of treatment

An exploratory pooled analysis indicates that the Lung Immune Prognostic Index score is associated with overall survival and progression-free survival in metastatic non-small-cell lung cancer patients receiving immune checkpoint inhibitors, targeted therapy, or cytotoxic chemotherapy.

31-07-2019 | Oncology | News | Article

Durable survival with nivolumab in patients with advanced RCC, NSCLC

Five-year data from the phase I CA209-003 trial indicate that the PD-1 inhibitor nivolumab is associated with long-term survival benefits among heavily pretreated patients with advanced renal cell carcinoma or non-small-cell lung cancer.

29-07-2019 | Oncology | News | Article

Hurricane disruption quantified for lung cancer radiotherapy

Hurricane disasters significantly and adversely impact the overall survival of patients undergoing definitive radiotherapy for locally advanced non-small-cell lung cancer, study findings suggest.

24-07-2019 | Oncology | News | Article

HBV reactivation risk ‘moderate to high’ for EGRF–TKI-treated NSCLC

Patients with non-small-cell lung cancer undergoing treatment with an EGFR–tyrosine kinase inhibitor may have a clinically meaningful risk for reactivation of unresolved hepatitis B virus infection during treatment, study findings indicate.

22-07-2019 | Oncology | News | Article

Local ablative therapy–pembrolizumab benefit suggested for metastatic NSCLC

Data from two phase II studies published in JAMA Oncology lend support to the sequential use of local ablative therapy and PD-1 blockade in patients with metastatic non-small-cell lung cancer.

18-07-2019 | Oncology | News | Article

Genomic markers of brain metastasis risk identified in NSCLC

Researchers have identified key genomic alterations in brain metastases matched to primary non-small-cell lung cancer that could serve as prognostic markers and potential therapeutic targets.

16-07-2019 | Oncology | News | Article

Phase I data support dual VEGFR2, PD-1 inhibition

Phase I study data suggest that ramucirumab plus pembrolizumab is a feasible treatment option for patients with previously treated advanced non-small-cell lung cancer, urothelial carcinoma, and gastric or gastroesophageal junction adenocarcinoma.

12-07-2019 | Oncology | News | Article

Low-dose CT provides superior screening for lung cancer death in high-risk smokers

Findings from an extended follow-up of the National Lung Screening Trial maintain that low-dose computed tomography screening significantly reduces risk for lung cancer death versus chest radiography screening among high-risk current and former smokers.

Image Credits